| 1 |
34819663 | The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. | 2021 Dec |
1 |
| 2 |
31943796 | Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. | 2020 Mar |
1 |
| 3 |
30660696 | Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. | 2019 Mar |
4 |
| 4 |
30662002 | Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. | 2019 Mar |
1 |
| 5 |
29550682 | Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. | 2018 Apr 15 |
2 |
| 6 |
29650534 | Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. | 2018 Jun |
1 |
| 7 |
29744867 | P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. | 2018 Oct 15 |
7 |
| 8 |
30149189 | Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. | 2018 Nov 30 |
1 |
| 9 |
30322862 | Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. | 2018 Dec 15 |
5 |
| 10 |
29048652 | Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. | 2017 Nov |
2 |